AbbVie Inc. logo

AbbVie Inc. (ABBV)

Market Closed
26 Feb, 20:00
NYSE NYSE
$
224. 69
-2.23
-0.98%
$
397.32B Market Cap
42.2 P/E Ratio
1.63% Div Yield
3,977,866 Volume
10.28 Eps
$ 226.92
Previous Close
Day Range
221.12 227.78
Year Range
164.39 244.81
Want to track ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ABBV earnings report is expected in 55 days (23 Apr 2026)
AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug

AbbVie Takes $3.5B Impairment Charge for Failed Schizophrenia Drug

AbbVie (ABBV) shares fell Friday after the biotech firm announced it would take an estimated $3.5 billion impairment charge because of the failure of one of its drugs.

Investopedia | 1 year ago
MoneyShow's Best Investment Ideas For 2025: Part 2

MoneyShow's Best Investment Ideas For 2025: Part 2

MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with turnaround potential, along with some speculative plays and ETFs. Part 2 of this series includes Neo Performance Metals, Fannie Mae, Agnico Eagle, AbbVie, Morgan Stanley and Nomura Holdings, among others.

Seekingalpha | 1 year ago
Abbvie to record $3.5 bln charge related to schizophrenia drug

Abbvie to record $3.5 bln charge related to schizophrenia drug

Abbvie said on Friday it will record a charge of about $3.5 billion related to its experimental schizophrenia drug, emraclidine, which recently failed in two mid-stage studies.

Reuters | 1 year ago
AbbVie's Stock Is Unfairly Cheap

AbbVie's Stock Is Unfairly Cheap

AbbVie's Stock Is Unfairly Cheap

Seekingalpha | 1 year ago
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?

Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 1 year ago
AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs

AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs

ABBV lowers adjusted earnings guidance for 2024 from $10.90-$10.94 per share to $10.02-$10.06 after incurring $1.6 billion in acquisition expenses in Q4.

Zacks | 1 year ago
AbbVie cuts 2024 profit forecast on acquisition expenses

AbbVie cuts 2024 profit forecast on acquisition expenses

AbbVie lowered its 2024 adjusted profit forecast on Monday as the drugmaker incurred $1.6 billion in acquisition expenses related to milestone payments as well as research-and-development costs.

Reuters | 1 year ago
The Smartest Dividend Stocks to Buy With $500 Right Now

The Smartest Dividend Stocks to Buy With $500 Right Now

Want to make a lot of money in the stock market without lots of stress? Buy and hold well-established companies that pay and increase dividends year after year.

Fool | 1 year ago
2 No-Brainer Dividend Stocks to Buy With $250 in 2025

2 No-Brainer Dividend Stocks to Buy With $250 in 2025

When it comes to dividend investing, there are two basic paths you can take. You could seek out businesses that are raising their payouts at a rapid pace, but these stocks tend to offer low yields.

Fool | 1 year ago
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade

3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade

If you're worried about having enough passive income to maintain your lifestyle during retirement, you're not alone. Having to spend more just to maintain their current standard of living is a constant concern for most families.

Fool | 1 year ago
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga | 1 year ago
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer

The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer

Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.

Zacks | 1 year ago
Loading...
Load More